Our findings indicated that, although lenvatinib initially inhibited ERK1/2 activity in HCC cells, a subsequent rebound in ERK1/2 activity may contribute to the emergence of lenvatinib resistance. The gene discussed is MAPK3; the disease is hepatocellular carcinoma.